7jvvpnnssatlstb2rj4a

Overactive bladder: Medication adherence

0.5 CME Credit hours

Course Title: Strategies to improve medical adherence and clinical management of overactive bladder - Medication adherence

Gain CME credit through our ACCME Accredited partner CME Outfitters


More than 50% of patients on medication for symptoms of overactive bladder (OAB) do not adhere their medication regiment

Overactive bladder (OAB) is a highly prevalent disorder which progresses dynamically over time and is characterised by both considerable incidence and remission rates. Increased symptom severity has been a driving force for patients to seek treatment.

OAB is a heterogeneous condition with a multifactorial underlying pathophysiology. The symptoms are treated in order to prevent worsening of the condition. More than 50% of patients on medication for symptoms of overactive bladder (OAB) do not adhere their medication regiment and 50 % of these stops within the first 6 months.

Use of certain medications such as anticholinergic drugs along with non-pharmacological therapies has shown to increase the success rate for the treatment of OAB. These drugs relax the detrusor muscle and consequently improve symptoms. Sometimes combination drugs can be beneficial. Medication is part of the treatment, but adherence to medication is what gives the desired results. How do we get patients to adhere to the treatment for better results? Why do patients not continue to take prescribed medication? What would be the strategies to improve compliance? This part of the OAB series deals with these issues. Take the course and find out.

Learning Objectives Of The Course
  1. Identify, discuss, and work with patients to overcome barriers to adherence to agree upon treatment plans for the management of overactive bladder (OAB)
  2. Initiate a communication dynamic that provides information on current and emerging treatments for overactive bladder (OAB) and the impact of medication adherence on patient health outcomes
Finance Support


Supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.

Your Instructor


CME Outfitters
CME Outfitters

Since 2002, CME Outfitters has delivered innovative evidence-based educational activities to thousands of clinicians each year and offers expert accreditation and outcome services for non-accredited organizations. CME Outfitters focuses on delivering education to primary care, specialty audiences and community-based clinicians with strong expertise in neuroscience, gastroenterology, dermatology, rheumatology, immunology, virology, transplant, and cardiology. CME Outfitters is certified as a women’s business enterprise through the Women’s Business Enterprise National Council (WBENC), the nation’s largest third-party certifier of businesses owned and operated by women in the United States Click here to learn more


Sender Herschorn, BSc, MDCM, FRCSC

Professor; Division of Urology
University of Toronto
Head of the Urodynamics Laboratory; Sunnybrook Health Sciences Centre; Toronto, ON;Canada

Christopher Chapple, BSc, MD, FRCS (Urol), FEBU

Consultant Urological Surgeon
Royal Hallamshire Hospital
Honorary Senior Lecturer of Urology, University of Sheffield; Visiting Professor of Urology, Sheffield Hallam University; Chairman of the International Relations Office, European Association of Urology Sheffield, UK

Michael B. Chancellor, MD

Professor and Director of Neurourology
Oakland University, William Beaumont School of Medicine
Royal Oak, MI

Why take this course?
  1. Increase your knowledge and skills- this course will and help you identify cases of OAB, help you evaluate them and overcome barriers. Teach you strategies for medical adherence in such cases
  2. CME Certification
  3. Credit hours gained- 0.5 hrs
Target audience
  1. General Physicians
  2. Specialists
  3. Interns
  4. Residents
Course format


This course is provided in the form of a SCORM file. Upon completion of this course, please complete the post-test and the evaluation so as to apply for your CME certification. A passing rate of 75% is required to earn CME credit.

Basic requirement


Participant should have an MBBS degree

Accreditation and designation statement


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC and CME Master. CME Outfitters, LLC is accredited by the ACCME to provide continuing medical education for physicians.


CME Outfitters, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosure statement

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty Disclosures:

Sender Herschorn, BSc, MDCM, FRCSC
Research/Grants: Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.
Speakers Bureau: Allergan Inc.;Astellas Pharma Inc.; Eli Lilly and Company; Pfizer Inc.
Consultant: Allergan Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Pfizer Inc.

Christopher Chapple, BSc, MD, FRCS (Urol), FEBU
Research/Grants: Allergan Inc,; Astellas Pharma Inc.; Pfizer Inc.; Recordati S.p.A.
Speakers Bureau: Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.; Ranbaxy Laboratories Limited; Recordati S.p.A.
Consultant: Allergan Inc.; American Medical Systems, Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Ono Pharmaceutical Co., Ltd; Pfizer Inc.; Recordati S.p.A.

Michael B. Chancellor, MD
Research Support: Allergan Inc.; Cook MyoSite, Inc.;Medtronic, Inc.
Consultant: Allergan Inc.;Astellas Pharma US, Inc.;Cook MyoSite, Inc.; Lipella Pharmaceuticals Inc.